Valuation: Prenetics Global Limited

Market Cap 330M 288M 266M 244M 463M 31.71B 471M 3.17B 1.24B 15.5B 1.24B 1.21B 53.41B P/E 2026 *
-6.65x
P/E 2027 * -59.8x
Enterprise Value 330M 288M 266M 244M 463M 31.71B 471M 3.17B 1.24B 15.5B 1.24B 1.21B 53.41B EV / Sales 2026 *
1.53x
EV / Sales 2027 * 0.87x
Free-Float
85.05%
Yield 2026 *
-
Yield 2027 * -
1 day-7.82%
1 week+18.09%
Current month+2.41%
1 month-5.64%
3 months+10.31%
6 months+31.67%
Current year+24.32%
1 week 16.84
Extreme 16.84
22.65
1 month 15.91
Extreme 15.91
22.65
Current year 14
Extreme 14
23.63
1 year 7.18
Extreme 7.175
23.63
3 years 2.85
Extreme 2.85
23.63
5 years 2.85
Extreme 2.85
131.25
10 years 2.85
Extreme 2.85
131.25
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 52 01/01/2014
Chief Executive Officer 47 01/01/2014
Director of Finance/CFO 41 01/01/2018
Director TitleAgeSince
Director/Board Member 60 13/06/2024
Chairman 47 01/01/2014
Director/Board Member - 16/02/2026
Date Insider Type Main position Quantity % Market Cap.
10/07Other

CFO of IM8 (US) LLC

56,851 0.3729%
04/07Fiscal year

Director

4,000 0.0262%
15/06Fiscal year

Director

31,746 0.2082%
Change 5-day change 1-year change 3-year change Capi.($)
-7.82%+18.09%+137.34%+49.37% 330M
+0.35%-6.21%-32.11%-17.29% 155B
+1.48%-1.88%-9.81%-8.19% 103B
-1.89%-4.20%+0.65%+54.93% 57.7B
-1.11%+1.09%+37.83%+53.63% 52.27B
+2.81%+2.87%-13.14%-40.29% 42.68B
+2.02%-2.13% - - 33.35B
-1.88%-1.80%-14.21%-47.04% 28.06B
+0.38%+1.50%+62.41%-6.78% 25.36B
-0.63%+4.57%-3.37%-18.03% 21.03B
Average -0.64%+2.01%+18.40%+2.26% 51.93B
Weighted average by Cap. +0.31%-1.70%-6.98%-2.33%

Financials

2026 *2027 *
Net sales 216M 189M 174M 160M 303M 20.79B 309M 2.08B 816M 10.16B 811M 793M 35.02B 378M 330M 304M 280M 530M 36.33B 539M 3.64B 1.43B 17.76B 1.42B 1.39B 61.2B
Net income -79.79M -69.76M -64.36M -59.16M -112M -7.68B -114M -768M -301M -3.75B -300M -293M -12.93B -746K -652K -601K -553K -1.05M -71.75M -1.07M -7.18M -2.82M -35.07M -2.8M -2.74M -121M
Net Debt - -
Logo Prenetics Global Limited
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.
Employees
98
Date Price Change Volume
15/07/26 USD 19.58 -7.82% 912,720
14/07/26 USD 21.24 +13.70% 802,606
13/07/26 USD 18.68 +4.59% 166,274
10/07/26 USD 17.86 +0.06% 107,713
09/07/26 USD 17.85 +7.66% 84,182
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
19.58USD
Average target price
34.20USD
Spread / Average Target
+74.67%

Quarterly revenue - Rate of surprise